Taken together, our results suggest that bispecific targeting of ErbB2 and ErbB3 with ALM may be efficacious in vivo against breast cancers with a wider range of ErbB2 expression than those amenable to the trastuzumab therapy available at present. Here, ERBB3 is linked to breast carcinoma.